Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
Company research
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing precisely targeted therapies that modulate immune cell maturation and function to treat cancers, T-cell lymphomas, autoimmune diseases, and inflammatory conditions. The company's lead product candidate, soquelitinib, a first-in-class oral ITK inhibitor, is currently advancing through a Phase 3 clinical trial for relapsed T-cell lymphomas and a Phase 1 trial for atopic dermatitis, alongside a broader pipeline that includes adenosine pathway inhibitors and other immune modulators. Founded in 2014 and led by co-founder and CEO Richard A. Miller, Corvus has a market capitalization of approximately $1.2 billion and held approximately $236.7 million in cash as of mid-2025, supported by recent public equity offerings that have extended its operational runway. As a pre-revenue company, Corvus continues to incur significant operating losses and relies on capital markets and potential third-party collaborations to finance its clinical development programs.
Research reports
Aggregates five Wall Street analysts with a Strong Buy consensus rating, highlighting positive Phase 1b/2 atopic dermatitis data for soquelitinib, a $27–34 price-target range, and pipeline upside estimated around 3.1 billion of potential value, while noting financing and development risks typical of early-stage biotech.
Orbyd · June 21, 2026CRVS stock analysis — Corvus Pharmaceuticals, Inc. — Orbyd dossierPresents a detailed trading-oriented thesis arguing that the key Phase 1 atopic-dermatitis binary has “resolved” positively but the stock sold off, leaving shares base-building around 12 dollars with no near-term catalyst and advising investors to wait for a higher-low and 50-day moving-average reclaim before re-entering, while outlining both a multi-year upside case around Phase 3 PTCL data and meaningful execution, durability, and China JV risks.
TrendMatrix Research · June 5, 2026Corvus Pharmaceuticals, Inc. (CRVS) Stock AnalysisRates CRVS a “Hold” with moderate conviction, citing a roughly 0.99 billion dollar market cap just below its quality screen, mixed technicals, a model take-profit target of 29 dollars versus an 11.12 dollar spot price, and an 11.3:1 stated reward-to-risk, but flags weak momentum, cash burn, volatility, and sub-threshold market cap as key reasons not to initiate new positions.
Simply Wall St (hosted On Moomoo) · May 14, 2026Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford to InvestFocuses on cash-burn analysis, noting CRVS had about 237 million dollars of cash and no debt as of March 2026 with roughly 35 million dollars of annual cash burn, implying a cash runway of around 6.7 years, and concludes management appears to be handling spending prudently even as burn has risen, though continued investment needs and biotech execution risk remain.
WallStreetZen · April 23, 2026NASDAQ: CRVS Corvus Pharmaceuticals Inc StockUses a DCF-based “fair value” estimate of about 0.05 dollars per share versus a 16 dollar price to argue CRVS screens as extremely overvalued on its intrinsic-value model, pairing this with negative earnings, zero revenue, and high price-to-book, and ultimately assigning only a “Hold (C)” quant rating while highlighting balance-sheet strength and extensive news-flow as partial offsets.
Simply Wall St (via Yahoo Finance) · March 13, 2026Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi‑Year Share Price GainsUses a two-stage discounted cash flow model and supplementary valuation checks to argue CRVS remains materially undervalued despite a 90 percent-plus three‑month gain and strong multi‑year share-price performance, estimating a per-share intrinsic value in the mid‑50s versus a mid‑teens market price and flagging the resulting sizeable discount as the core of the bullish thesis, while acknowledging cash-burn, biotech risk, and sensitivity to assumptions.